Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Leases (2021 - 2025)

Prime Medicine's Current Leases history spans 5 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Current Leases rose 125.15% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, up 125.15%, while the annual FY2025 figure was $8.1 million, 125.15% up from the prior year.
  • Current Leases reached $8.1 million in Q4 2025 per PRME's latest filing, up from $7.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $13.5 million in Q2 2023 to a low of $3.6 million in Q4 2024.
  • Average Current Leases over 5 years is $8.4 million, with a median of $7.7 million recorded in 2025.
  • Peak YoY movement for Current Leases: plummeted 61.39% in 2024, then surged 125.15% in 2025.
  • A 5-year view of Current Leases shows it stood at $7.3 million in 2021, then surged by 59.41% to $11.7 million in 2022, then fell by 20.68% to $9.3 million in 2023, then crashed by 61.04% to $3.6 million in 2024, then soared by 125.15% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Current Leases are $8.1 million (Q4 2025), $7.7 million (Q3 2025), and $7.3 million (Q2 2025).